Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Pivotal human trial | 26-week, placebo-controlled Phase 3 RCT (Falutz et al., NEJM 2007) |
| FDA approval | Approved as Egrifta, Egrifta SV, Egrifta WR - one narrow indication only |
| Approved population | HIV-infected adults with lipodystrophy and excess visceral fat |
| Off-label research-chemical use | No trial data exists for that population or those purposes |
| Regulatory status | Prescription-only drug (approved use); unregulated when sold as research chemical |
What Tesamorelin Is
Tesamorelin is a synthetic, stabilized analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland through the body's own GHRH receptor pathway. Unlike most peptides covered on this site, it's a genuine FDA-approved prescription drug, marketed under the brand names Egrifta, Egrifta SV, and Egrifta WR by Theratechnologies, for one specific, narrow indication: reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. See the full Tesamorelin reference page for approved dosing by formulation and the off-label research landscape.
The Pivotal Human Trial
Tesamorelin's approval rests on a 26-week, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial in HIV-infected patients with lipodystrophy (Falutz et al., published in the New England Journal of Medicine, 2007). The trial used CT scanning to measure visceral adipose tissue directly, rather than relying on weight or waist circumference alone, and found a statistically significant, selective reduction in visceral fat in the tesamorelin group versus placebo, along with secondary improvements in triglycerides and total cholesterol.
That trial design, randomized, blinded, placebo-controlled, with an objective imaging-based primary endpoint, is the kind of evidence most research peptides covered on this site never go through. It's also why Tesamorelin's regulatory status differs so sharply from compounds with similar-sounding mechanisms but no trial history of their own.
Why this matters: the strength of Tesamorelin's evidence is real, but it's also narrow. The trial was conducted in one specific patient population for one specific outcome. It says nothing directly about using tesamorelin for general fat loss, bodybuilding, or anti-aging purposes in people without HIV-associated lipodystrophy.
How Narrow Is the Approved Indication, Really
Tesamorelin is FDA-approved under the brand names Egrifta, Egrifta SV, and Egrifta WR specifically for reducing excess visceral abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general fat loss, bodybuilding, or anti-aging use, even though it's the same approved molecule in those other contexts. Any use outside the approved indication, whether with a legitimately prescribed product or a research-chemical vial, is off-label and unsupported by the pivotal trial's data.
There's also a dosing detail worth flagging on its own: Tesamorelin's half-life is only about 11 minutes according to its FDA label, yet its approved regimen is once-daily subcutaneous injection rather than multiple-times-daily dosing. That's because the approved schedule reflects what the pivotal trial actually tested and showed benefit from, not something derived from pharmacokinetics alone.
Evidence Gaps and Regulatory Status
The gap in Tesamorelin's evidence picture isn't whether human trial data exists, it clearly does, but how far that data extends. No placebo-controlled trial has tested tesamorelin for general fat loss, muscle gain, or anti-aging use in people without HIV-associated lipodystrophy, which is the population and goal most off-label and research-chemical use actually targets. A legitimately manufactured, prescribed Egrifta product used for its approved indication under medical supervision is also a meaningfully different situation than an unregulated research-chemical vial used off-label: product purity, dosing accuracy, and medical oversight aren't guaranteed outside the approved pathway, even though the underlying molecule and trial data are the same.
Bloodwork to Track
Tesamorelin's own pivotal trial tracked IGF-1, glucose, and lipid panel values (triglycerides, total cholesterol) alongside its visceral fat outcome, since GHRH-pathway stimulation affects downstream growth hormone and IGF-1 levels and can shift lipid and glucose metabolism. See the peptide bloodwork guide for what a baseline and follow-up panel typically includes.
Related Reading
For dosing by formulation and the off-label research landscape, see the Tesamorelin reference page. For how Tesamorelin's evidence and regulatory status compare to a research-chemical GHRH analog, see Tesamorelin vs CJC-1295. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.